



Deadline	<b>Thu 11 Apr 2024 17:00 Brussels time (IOCB deadline Thu 4 Apr 2024)</b>
Call name	HORIZON-HLTH-2024-DISEASE-08-20: Pandemic preparedness and response: Host-pathogen interactions of infectious diseases with epidemic potential
www	<a href="https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/horizon-hlth-2024-disease-08-20">https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/horizon-hlth-2024-disease-08-20</a>
Focused on	<p>Funding consortia to study innovative approaches to characterise host-pathogen interactions with a view to inhibit viral replication, viral proteases, viral exit strategies and to develop therapeutic antibodies and vaccines that target viruses with high epidemic or pandemic potential for the EU. Proposals should focus on the following viruses: Hendra and Nipah virus, Lassa virus, Crimean Congo haemorrhagic fever virus, Rift Valley fever virus, Ebola and Marburg virus, Dengue virus, Yellow Fever virus, Zika virus, West Nile fever virus and Chikungunya virus.</p> <p>Proposals should address several of the following areas:</p> <ul style="list-style-type: none"> <li>• Identification and characterisation of receptors on the host cell that enable the docking and internalisation of a virus with a particular emphasis on the diversity of cellular entry receptors and tissue specificity.</li> <li>• Identification and characterisation of viral surface proteins that are capable of interacting with host target cells.</li> <li>• Characterisation of the mechanism of viral uptake in the host cell with regard to the topology and the dynamics of the host receptor – virus ligand interaction.</li> <li>• Identification of receptor and ligand (sub)units that could be targeted by preventive or therapeutic intervention.</li> </ul>
PI	Researchers of any nationality conducting their research in any EU member state or associated country
Eligible organisation	Universities, research organisations, SMEs, start-ups, industrial partners established in an EU member state or an associated country.
Target group	Consortium of researchers that includes at least three independent legal entities, each one established in a different Member State or Associated Country and with at least one of them established in a Member State.
Expected outputs	Open Access (J) reviewed specialist articles; movement of new technology up the TRL scale towards technology development
Call opens	Thur 26 Oct 2023
IOCB deadline	<b>Thu 4 Apr 2024</b>
Final deadline	<b>Thu 11 Apr 2024 17:00 Brussels time</b>
Evaluation results	September 2024 (indicative)
Signature of agreement	November 2024 (indicative)
Earliest date of implementation	-
Latest date of implementation	-
Sustainability	None
Reporting	one report every 18 months
Project duration (min-max)	Unlimited (usually 36 – 48 months)
Allocation for the call	50 M EUR (5 projects)
Project budget (min-max)	<b>7 – 8 M EUR</b> per project
Success rate	n.a.
Eligible costs	Direct costs: personnel costs, travel expenses, equipment, goods & services, outsourcing (subcontracting); indirect costs: overheads max 25% of the total eligible direct costs
Reimbursement	<b>100 %</b>
Mode of funding	Ex-ante
Language of application	English
Provider	European Commission Horizon Europe, <a href="https://www.horizontevropa.cz/cs/struktura-programu-he/globalni-vyzvy-konkurenceschopnost/klastr-1-zdravi/informace?storiesType=0">https://www.horizontevropa.cz/cs/struktura-programu-he/globalni-vyzvy-konkurenceschopnost/klastr-1-zdravi/informace?storiesType=0</a> NCP: Technology Centre CAS, <a href="http://www.tc.cz">www.tc.cz</a> ; Monika Vraiová: <a href="mailto:vraiova@tc.cz">vraiova@tc.cz</a> , tel. +420 720 025 593
Call identifier	Pandemic Preparedness and response: Host-pathogen interactions of infectious diseases with epidemic potential 2024 (HORIZON-HLTH-2024-DISEASE-08-20)
Call info	The Cluster 1 health calls are targeted at specific topics defined by the European Commission. This call is asking for proposals of innovative approaches to characterise host-pathogen interactions with a view to inhibit viral replication, viral proteases, viral exit strategies and to develop therapeutic antibodies and vaccines that target viruses with high epidemic or pandemic potential for the EU.

Conditions / Restrictions	Proposal must be submitted by the coordinator, on behalf of a consortium that includes at least three independent legal entities, each one established in a different Member State or Associated Country and with at least one of them established in a Member State. The legal entities may for example be universities, research organisations, SMEs, start-ups, industrial partners or natural persons. Sections 1 to 3 of the part B of your proposal, corresponding respectively to the evaluation criteria Excellence, Impact, and Quality and Efficiency of the Implementation, must consist of a <b>maximum of 45 A4 pages</b> . Excess pages will be automatically made invisible, and will not be taken into consideration by the evaluators.
Proposal consists of	On-line application on the Funding&Tenders Portal: <a href="https://webgate.ec.europa.eu/cas/login">https://webgate.ec.europa.eu/cas/login</a> 1) <b>Administrative form</b> (Part A, on-line on the Funding&Tenders Portal): (i) General information: Abstract, Declarations; (ii) Administrative data of participating organisations: Organisation data, Department, Main contact person, Researchers involved in proposal and their career stages, Role of participating organisation, up to 5 publications relevant for call content, up to 5 previous projects, significant infrastructure relevant to proposal, GEP yes/no tickbox; (iii) Budget – budget table; (iv) Ethics and security issues tables; (v) Other questions (applicant & Project Office) 2) <b>Research proposal</b> (Part B technical description, use template, max 45 A4 pages, 50 pages for topics using lump sum funding): (a) Excellence; (b) Impact; (c) Quality and efficiency of the implementation 3) <b>Other documentation</b> (annexes) needed on <b>ethics</b> and <b>security</b> issues, on <b>clinical trials</b> or <b>financial support to third parties</b> , if relevant (Project Office & applicant)
Evaluation criteria	<b>Remote scoring by evaluators according to the criteria below.</b> Evaluation committee will make a final decision based on the remote evaluators' reports. <b>Excellence (Threshold: 4/5)</b> <ul style="list-style-type: none"> <li>Clarity and pertinence of the project's objectives, and the extent to which the proposed work is ambitious, and goes beyond the state of the art.</li> <li>Soundness of the proposed methodology, including the underlying concepts, models, assumptions, inter-disciplinary approaches, appropriate consideration of the gender dimension in research and innovation content, and the quality of open science practices, including sharing and management of research outputs and engagement of citizens, civil society and end users where appropriate.</li> </ul> <b>Impact (Threshold: 3/5)</b> <ul style="list-style-type: none"> <li>Credibility of the pathways to achieve the expected outcomes and impacts specified in the work programme, and the likely scale and significance of the contributions from to the project.</li> <li>Suitability and quality of the measures to maximise expected outcomes and impacts, as set out in the dissemination and exploitation plan, including communication activities.</li> </ul> <b>Quality and efficiency of the implementation (Threshold 3/5)</b> <ul style="list-style-type: none"> <li>Quality and effectiveness of the work plan, assessment of risks, and appropriateness of the effort assigned to work packages, and the resources overall.</li> <li>Capacity and role of each participant, and the extent to which the consortium as a whole brings together the necessary expertise.</li> </ul>
Research areas	Infectious diseases
Call workshop	Recording of Horizon Europe Cluster 1 (2024 calls) information day (1 June 2023) <a href="https://research-innovation-community.ec.europa.eu/events/OSYIT74DBdeo397co1CGj/overview">https://research-innovation-community.ec.europa.eu/events/OSYIT74DBdeo397co1CGj/overview</a>
IOCB contact	Please inform the IOCB Project Office about your intention to apply. Do not hesitate to contact us anytime for consulting, discussion or help. Jitka Šilerová, <a href="mailto:jitka.silerova@uochb.cas.cz">jitka.silerova@uochb.cas.cz</a> , +420 220 183 229 Veronika Palečková, <a href="mailto:veronika.paleckova@uochb.cas.cz">veronika.paleckova@uochb.cas.cz</a> , +420 220 183 266 Blanka Collis, <a href="mailto:blanka.collis@uochb.cas.cz">blanka.collis@uochb.cas.cz</a> , +420 220 183 527 Lenka Štěrbová, <a href="mailto:lenka.sterbova@uochb.cas.cz">lenka.sterbova@uochb.cas.cz</a> , +420 220 183 179
Download documents	Pandemic preparedness 2024 summary Cluster 1 Health work programme 2023-2024 HEU Standard Application Form template